EasySep™小鼠TIL（CD45）正选试剂盒
Cell Therapy Development
-
Non-Viral CRISPR Knock-In Anti-B7-H3 CAR-T Cells Are Amenable for Treatment of Subtypes of Small Cell Lung Cancer In this webinar, Scientist Vimal Keerthi discusses his work on identifying CD276 (B7-H3) overexpression in primary human SCLC and developing a non-viral CRISPR-Cas9 knock-in (CKI) based platform against B7-H3 to manufacture CAR T cells for the treatment of SCLC. He demonstrates the feasibility of this CAR T manufacturing platform and how this provides a blueprint for immediate clinical translation, overcoming the bottleneck of viral vector production.
This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts. -
Advances in Point-of-Care Cell Engineering—What Are You Feeding Your CAR T Cells? In this webinar, Dr. Julian J. Lum discusses key factors to consider when choosing metabolic assays and how they can be used to assess cell function. Additionally, he discusses the metabolic characteristics of different commercially available cell culture media formulations as well as the importance of assessing the array of media products and their impact on metabolism.
This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts. -
Next-Generation Cell Isolation Solutions for T Cell Therapy Research Join this talk, presented by Dr. Amanda Durkin and Q&A guest Dr. Frann Antignano, to learn about STEMCELL’s cell isolation solutions for fast and easy T cell isolation. This presentation will also focus on large-scale research strategies by introducing our new mobilized leukopaks and feature the Easy 250 EasySep™ Magnet—a scalable and efficient system for manual column-free isolation.
This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts. -
Combining CAR T Cells with STING Agonists to Fight Solid Tumors In this webinar, Dr. Uslu describes how IMSA101 enhances CAR T function through STING agonist-induced IL-18 secretion and how these findings lay the foundation for advancing the combinatorial approach into a clinical setting.
This webinar is part of the “Translational T Cell Talks: Scaling for the Future” event hosted in collaboration with Scientist.com on June 11, 2024. View the rest of the talks and read the Q&A transcripts. -
Tools for Optimizing Human Immune Cell Research Obtaining consistent and reliable results when culturing immune cells can be challenging. Watch this webinar to discover how to obtain high yields of functional T cells, NK cells, B cells, dendritic cells, and macrophages for your research applications. The speaker, Evan Karas, also explains how to expand primary T cells without feeders or serum. -
Optimized Workflows for High-Efficiency Genome Editing in Stem and Primary Cell Types CRISPR-Cas genome editing in cell culture systems is a powerful technique for disease modeling and the development of cellular therapies. Compared to work with immortalized cell lines, genome editing of stem and primary cells presents unique challenges, including issues related to efficient delivery and expression of CRISPR machinery, clonogenicity, and cytotoxicity. In this webinar, our in-house expert, Dr. Ashley Watson, discusses optimized workflows for CRISPR-Cas9 genome editing in human pluripotent stem cells and primary T cells.
